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Open access under CC BYThe STAT6 (signal transducer and activator of transcription 6) protein facilitates T-helper cell 2 (Th2)
mediated responses that control IgE-mediated atopic diseases such as asthma. We have identiﬁed com-
pounds that bind to STAT6 and inhibit STAT6 tyrosine phosphorylation induced by IL-4. In the bronchial
epithelial cell line BEAS-2B, compound (R)-84 inhibits the secretion of eotaxin-3, a chemokine eliciting
eosinophil inﬁltration. (R)-84 appears to prevent STAT6 from assuming the active dimer conﬁguration
by directly binding the protein and inhibiting tyrosine phosphorylation.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
With an estimated prevalence of 100 million affected individu-
als worldwide, asthma is among the most common of chronic dis-
eases in developed world populations. The etiology of asthma is
complex, but a broad consensus holds that airway exposure to
allergens results in activation of antigen-speciﬁc Th2 cell develop-
ment and the secretion of Th2 cytokines such as IL-4 and IL-13,
which are critical regulators of inﬂammatory responses.1,2 The air-
ways of asthmatics are characterized by airway hyperreactivity
(AHR, deﬁned by exaggerated airﬂow obstruction in response to
bronchoconstrictors), mucus overproduction, and chronic eosino-
philic inﬂammation, all of which have been inferred to be mediated
by STAT6-dependent pathways. Genetic deletion of STAT6 in mice
broadly blunts Th2 axis responsiveness, and yields phenotypic evi-
dence that STAT6 is a central downstream mediator for airway
reactivity.3,4 Targeted expression of STAT6 in epithelial cells is suf-
ﬁcient for IL-13 induced AHR and mucus production.5 Because
STAT6-null mice are healthy under laboratory conditions, STAT6
has been considered a promising target for the treatment of
asthmatic disease in humans.: +1 617 643 3328.
eed).
-NC-ND license.Like other members of the STAT family, STAT6 has a dual role as
signaling molecule and transcription factor. Activation of STAT6 is
initiated by binding of cytokines IL-4 and IL-13 to their cognate
receptors, which leads to the activation of Janus tyrosine kinases
(JAKs) including JAK1, JAK2, JAK3, and Tyk2, which are associated
with the cytoplasmic tails of the receptors.6 The activated JAKs
phosphorylate receptor tyrosine residues, generating a docking site
for cytoplasmic STAT6. Following binding to the receptor phospho-
tyrosines by its SH2 domain, STAT6 becomes phosphorylated at
conserved tyrosine residue Y641 and undergoes dimerization med-
iated by phosphotyrosine–SH2 interaction. The activated STAT6 di-
mers translocate rapidly to the nucleus, where they induce gene
expression.
STAT proteins were originally thought to adopt a monomeric
state prior to activation.7 However, recent evidence suggests the
existence of an alternate inactive dimer state in which the tran-
scription factor resides prior to activation.8,9 The conformation of
this dimer is antiparallel in the case of STAT1.10,11 After tyrosine
phosphorylation, the antiparallel dimers are transformed into a
parallel conﬁguration, which is established by mutual phosphoty-
rosine–SH2 interactions. In STAT1 this conformation change re-
sults in a 200-fold increase in DNA binding activity.12 If STAT6
were to undergo similar conformational changes they would take
place upon phosphorylation at Y641.
L. Zhou et al. / Bioorg. Med. Chem. 20 (2012) 750–758 751Because STAT proteins control fundamental processes in the
hematopoietic system and beyond, there is a growing interest in
discovering small molecule inhibitors of their action. To accom-
plish this, cell-based screening strategies have been widely utilized
to identify and evaluate compounds that can inhibit one or more
key steps involved in STAT activation, including recruitment to
cytokine receptors, phosphorylation, dimerization, and DNA bind-
ing. Additional efforts have been devoted to the design and/or
screening for inhibitors that can speciﬁcally inhibit key steps in-
volved in STAT activation. For example, inhibitors that target the
STAT SH2 domain,13–16 STAT nuclear translocation,17 and dimeriza-
tion of phosphorylated STAT (using dominant-negative STAT pep-
tides)18 have been reported. Notably only very few STAT6
inhibitors have been disclosed to date,18–22 and most of them have
been identiﬁed through IL-4 or STAT6 reporter-based screening.20–
22 The mechanisms by which these STAT6 inhibitors act has yet to
be established. Since cell-based reporter assays are not designed to
distinguish STAT6-speciﬁc inhibition from that caused by the inhi-
bition of a variety of upstream factors including cytokines, cytokine
receptors, and JAKs, such screens may not select inhibitors that are
speciﬁcally targeted to STAT6.
To discover speciﬁc STAT6 inhibitors, an afﬁnity selection-mass
spectrometry (AS-MS) method23–25 was applied to identify small
molecules that bind to recombinant human STAT6 speciﬁcally.
Brieﬂy, mass-encoded libraries of small molecule compounds were
exposed to puriﬁed target protein. The target with any bound mol-
ecules was rapidly separated from free compounds by size exclu-
sion chromatography, and the bound compounds were identiﬁed
by LC/MS/MS. Following conﬁrmation of hits by re-synthesis indi-
vidual candidates were advanced for further characterization. The
selected binders were further analyzed by cell-based reporter as-
says. A lead compound, (R)-76, was identiﬁed. Both (R)-76 and
its analog (R)-84 demonstrated sub lM afﬁnity for recombinant
STAT6 by surface plasmon resonance (SPR) analysis. Both com-
pounds inhibit STAT6-dependent signaling events in a reporter-
based assay and block eotaxin-3 secretion by bronchial epithelial
cells. STAT6 tyrosine phosphorylation is inhibited by these com-
pounds, which may prevent the formation of STAT6 dimer in the
active parallel conﬁguration.2. Results and discussion
2.1. Synthesis of (R)-76 and (R)-84
Compounds (R)-76 and (R)-84 were synthesized following the
procedures outlined in Scheme 1. Suzuki coupling between 4-bro-
mopyridine-2,6-dicarboxyl methyl ester and the boronic acid of
benzothiophene and that of N-methyl-indole, respectively gave
dicarboxylic esters that were hydrolyzed and condensed with ami-
noethyl-pyridine and (R)-3-methyl-2-butylamine in the presence
of HOBt/EDCI catalyst to afford (R)-76 and (R)-84, respectively.
The condensation reactions may be carried out in a step-wise fash-
ion, as indicated for the preparation of (R)-76, or in a one-pot
process, as exempliﬁed by the preparation of (R)-84.2.2. Inhibition of STAT6 signaling
Recombinant human STAT6 was prepared following baculoviral
infection of insect cells. The protein was screened against approx-
imately 10 million compounds using Afﬁnity Selection-Mass Spec-
trometry screening23–25 to identify compounds that speciﬁcally
bind to STAT6 protein. A number of compounds were selected
and further tested for their ability to inhibit STAT6 signaling in a
cell-based assay using a STAT6 reporter created by inserting six
copies of an IL-4 responsive element in front of the Photinus pyralisluciferase gene.26 The assay was designed to measure the degree of
transcriptional activation of STAT6 stimulated by IL-4, and the ef-
fect of the compounds on such transcriptional activation. After
co-transfection of the reporter construct and an expression vector
encoding human STAT6, we detected a 30-fold increase in lucifer-
ase activity following exposure to IL-4 for 6 h (Fig. 2A). The induc-
tion was inhibited in the presence of a particular chemotype
represented by compound (R)-76 (Figs. 1 and 2A). Renilla reniformis
luciferase under the control of the Herpes simplex thymidine kinase
promoter was used as a control for transfection efﬁciency and cel-
lular toxicity. The Renilla luciferase activity was only slightly af-
fected by the compounds (data not shown), indicating that the
inhibition of STAT6 reporter was not due to some general toxic ef-
fect. The compounds did not affect Photinus luciferase activity per
se, as similar inhibition was observed when we used Renilla
luciferase in place of Photinus luciferase as the reporter (data not
shown). Based on the chemical structure of (R)-76, we designed
and synthesized a series of analogs and tested them in the reporter
assay. Among them compound (R)-84 was selected for further
analysis (Fig. 1). The IC50 values of the original lead compound
(R)-76 and the modiﬁed compound (R)-84 are 3.2 lM and
2.7 lM, respectively. Mouse STAT6 is inhibited with similar IC50
values by these compounds (data not shown). For comparison we
have included data for oxime 7Z (shown in Fig. 1), a previously de-
scribed STAT6 inhibitor,27 as a reference.
2.3. Inhibition of eotaxin-3 secretion
Eotaxins are important mediators of eosinophil recruitment and
activation in asthma. IL-4, IL-13 and TNF-a can induce secretion of
eotaxin-3,28 and eotaxin-3 secretion induced by IL-4 and IL-13 is
mediated by STAT6.29–32 To test if (R)-76 and (R)-84 can block
secretion elicited by these agents, we carried out an eotaxin secre-
tion assay using the bronchial epithelium cell line BEAS-2B. In this
line IL-4 treatment induces eotaxin-3 secretion to >1 ng/ml after
24 h of cytokine exposure (Fig. 2B). Prolonging incubation time
to 48 h increases accumulation to 2 ng/ml (Fig. 2C). BEAS-2B is
more sensitive than the A549 cell line for this induction (Fig. 2B).
(R)-84 was able to suppress eotaxoin-3 secretion at 10 lM
whereas 7Z and (R)-76 were not particularly effective (Fig. 2D).
The IC50 for (R)-84 was determined to be 2.74 lM, which is similar
to that determined by the reporter assay. Although (R)-76 and (R)-
84 bind equally well to STAT6 protein (see below), and (R)-76
shows similar activity in the reporter assay, (R)-76 is not as effec-
tive in the eotaxin-3 secretion assay. Figure 2E shows that eotaxin-
3 secretion is inducible by IL-4 and/or IL-13, and that induction is
further augmented when TNF-a is co-applied. At 10 lM concentra-
tion, (R)-84 is able to suppress induction effectively (Fig. 2E).
2.4. (R)-76 and (R)-84 directly inhibit tyrosine phosphorylation
of STAT6 without interfering with the interaction between
STAT6 and phospho-IL-4Ra
STAT6 tyrosine phosphorylation by activated JAK kinases is a
key step in STAT6 activation. In vivo this process involves the dock-
ing of STAT6 onto the cytoplasmic tail of phosphorylated IL-4Ra
mediated through speciﬁc interactions between the SH2 domain
of STAT6 and phosphorylated tyrosine residues on IL-4Ra. Since
STAT6 binding to IL-4Ra is necessary for STAT6 phosphorylation,
(R)-76 or (R)-84 could potentially inhibit STAT6 activation by
blocking receptor binding. To investigate this possibility, we exam-
ined the interaction between STAT6 and an IL-4Ra-derived peptide
representing the docking site. In an ELISA format, immobilized IL-
4R peptide and its phosphorylated counterpart p-IL-4R peptide
were tested for STAT6 recognition. As shown in Figure 3B, STAT6
binds to the phosphorylated p-IL-4R peptide with an EC50
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Figure 1. Compounds used in this study.
752 L. Zhou et al. / Bioorg. Med. Chem. 20 (2012) 750–758(132 nM) similar to that reported in the literature.7 The interaction
is not affected by any of the STAT6 inhibitors (Fig. 3C). This resultsuggests that these compounds do not interfere with the interac-
tion between IL-4Ra and the SH2 domain of STAT6.
We next tested if STAT6 tyrosine phosphorylation is inhibited.
In 293-EBNA cells transfected with human STAT6, IL-4 treatment
causes STAT6 to undergo tyrosine phosphorylation and the phos-
phorylated STAT6 can be detected with an anti-phospho-tyrosine
antibody (Fig. 3A). Because the induction occurs within minutes
of IL-4 addition, the inhibitory effects of the compounds were
tested by pre-incubating cells with different compounds at
10 lM for 1 h prior to IL-4 induction. After the addition of IL-4,
the cells were further incubated for 6 h, harvested, lysed and sub-
jected to immunoblot analysis. As shown in Figure 3A, (R)-76 and
(R)-84 inhibited STAT6 phosphorylation, whereas 7Z did not. This
indicates that the inhibition of STAT6 signaling by 7Z is via a differ-
ent mechanism than that of (R)-76 and (R)-84.
Because JAK kinases are responsible for IL-4/IL-13 induced
STAT6 phosphorylation, and JAK2 is commonly involved in the
STAT6 activation,33 we next tested if (R)-76 and (R)-84 could inhi-
bit JAK2 kinase activity. Figure 3D illustrates that neither (R)-76
and (R)-84 inhibited JAK2 up to 10 lM, whereas Pyridone 6, a
known JAK2 inhibitor, inhibited activity in a dose-dependent man-
ner. We conclude from these results that (R)-76 and (R)-84 specif-
ically inhibit STAT6 tyrosine phosphorylation primarily by directly
interacting with STAT6.
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Figure 2. Inhibition of STAT6 signaling in cell-based assays. (A) Induction of STAT6 reporter luciferase activity by IL-4 (10 ng/ml) in 293-EBNA cells, and inhibition by (R)-84
or (R)-76 at 10 lM. (B) Eotaxin-3 secretion in BEAS-2B and A549 cells after induction with various concentrations of IL-4 for 24 h. (C) Eotaxin-3 secretion in the BEAS-2B cell
line after IL-4 induction for 24 h and 48 h. (D) Inhibition of eotaxin-3 secretion by 7Z, (R)-76, or (R)-84 at 10 lM after 24 h IL-4 induction. (E) Secretion of eotaxin-3 induced
by IL-4 and IL-13, alone or in combination with TNF-a, and inhibition of each induction by (R)-84 at 10 lM. Error bars are sd; ⁄P <0.05, ⁄⁄P <0.01, ⁄⁄⁄P <0.001, ns, not signiﬁcant,
in two-tailed t-test.
L. Zhou et al. / Bioorg. Med. Chem. 20 (2012) 750–758 7532.5. SPR analysis of STAT6–inhibitor interactions
To characterize the interactions between STAT6 and the inhibi-
tors, surface plasmon resonance (SPR) technology was applied.
Recombinant STAT6 was immobilized to a BIAcore Series S Sensor
Chip CM5 by direct conjugation (amide formation) using an amine
coupling kit. Each analyte, (R)-76, (R)-84, or 7Z, was injected in the
mobile phase, and the binding of each compound to surface-bound
STAT6 was detected as a change of SPR response measured in res-
onance units (RU). The resulting SPR sensorgrams corresponding to
complex formation and dissociation were recorded (Fig. 4), from
which kinetic association rate (ka) and dissociation rate (kd)constants were derived by global ﬁtting of data to 1:1 Langmuir
binding model. Based on the kd and ka values, the equilibrium dis-
sociation constant (KD = kd/ka) can be calculated. As summarized in
Table 1, (R)-76 and (R)-84 exhibited very similar binding kinetics
and binding afﬁnity to STAT6, whereas 7Z showed a slower disso-
ciation rate and a signiﬁcantly slower association rate than others,
resulting in a much weaker binding afﬁnity.
It is also notable that the binding constants observed for com-
pounds (R)-76 and (R)-84 are similar to the IC50 values they exhib-
ited in STAT6 reporter assays (Fig. 2D). This correlation suggests
that direct STAT6 binding may be the major contributing factor
to the inhibition of STAT6 activity in the cell based assays.
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Figure 3. Effect of STAT6 signaling inhibitors on individual activation steps. (A) (R)-84 or (R)-76 inhibits IL-4 induced STAT6 phosphorylation as analyzed by western blot. (B)
Interactions between STAT6 and immobilized IL-4R derived peptides analyzed by ELISA. (C) Effect of STAT6 inhibitors on the STAT6/IL-4R interaction analyzed by ELISA. (D)
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inhibitors
Many members in the STAT family, including STAT1, STAT3,
STAT4, have been shown to form dimers in the non-phosphory-
lated state, in an antiparallel dimerization mediated by interac-
tions at the N-terminus of the protein.10,11 Upon tyrosine
phosphorylation, the STAT dimers change to a parallel dimer struc-
ture stabilized by SH2 domain-phosphotyrosine interaction. Since
STAT6 tyrosine phosphorylation is inhibited by (R)-76 and (R)-
84, we tested if these compounds would have any effect on STAT6
basal dimer formation. We constructed expression vectors encod-
ing STAT6 with an HA tag or a myc tag and cotransfected them
in equal proportion to allow the detection of randomly assorted
heterodimers forming after translation. Immunoprecipitation by
anti-HA agarose and blot detection with anti-myc antibody
showed that no difference in abundance of heterodimers could
be detected before or after IL-4 treatment (Fig. 5A). This result is
in agreement with observations of resting state STAT dimers made
elsewhere.10,11 (R)-76 and (R)-84 did not affect the STAT6 dimer
formation per se, but in their presence the dimer remained
unphosphorylated in an inactive conﬁguration even after IL-4
induction (Fig. 5B). Data presented in Figure 5 is also in agreement
with the results described in Figure 3A that 7Z does not inhibit
STAT6 phosphorylation.
3. Discussion
In previously reported campaigns to identify STAT6 inhibitors,
various strategies have been applied. These have included inhibi-
tion of SH2 domain interaction, inhibition of STAT6 and IL-4Rinteraction,34 inhibition of STAT nuclear translocation,17 and DNA
binding inhibition. To date there has been no report of which we
are aware in which full length recombinant STAT6 protein was
used as the target for compound screening.
The STAT6 inhibitors described here implicate an interference
site on STAT6 that involves tyrosine phosphorylation. The mecha-
nism of action appears to involve inhibition of STAT6 activation,
presumably by stabilization of the STAT6 dimer in an inactive con-
ﬁguration. Since structural studies on STAT dimers have
established that they undergo conformational changes from an
antiparallel to a parallel conﬁguration, binding of (R)-76 or
(R)-84 may have blocked such a conformational transition
(Fig. 6). However it is also possible that the inhibitors promote
the formation of an alternate dimer structure.
An SPR-based binding assay conﬁrmed that both (R)-76 and
(R)-84 directly interact with STAT6 with an afﬁnity in the sub
lM range. When tested in cell-based assays, the compounds
showed IC50 values in the lM range. Replacing the benzothiophene
moiety in (R)-76 with N-methyl-indole in (R)-84 markedly im-
proved inhibition efﬁcacy in various cell based assays, even though
(R)-76 and (R)-84 appear to have similar binding afﬁnity to STAT6
in vitro. While it is still unclear why (R)-84 shows superior activity
to (R)-76 in STAT6 inhibition in cell based assay, it is possible, for
example, that the molecules differ in their ability to obstruct other
conformation-sensitive components of STAT6 signaling.
After the conclusion of the present study, a recent report
described a non-agonist PPARc ligand blocking Cdk5-mediated
phosphorylation.36 It is noteworthy that the mechanism of action
bears some similarity to that proposed here, that is, the reported
inhibitory effect is mediated through binding to a transcriptional
factor, not to its kinase.
Figure 4. SPR sensorgrams of STAT6 binding by small molecule inhibitors (R)-84, (R)-76, and 7Z.
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Figure 5. STAT6 heterodimerization can be detected prior to IL-4 induction and is
not affected by inhibitors. (A) Immunoprecipitation (IP) with anti-HA followed by
immunoblot (IB) with anti-myc and anti-HA. (B) Re-probed with anti-phospho-
STAT antibody.
Table 1
Equilibrium dissociation constant (KD), association rate (ka), and dissociation rate (kd),
and v2 value obtained by global ﬁtting of SPR sensorgrams to a 1:1 Langmuir binding
model
Inhibitor ka (1/Ms) kd (1/s) KD (lM) v2
(R)-84 2.546  104 0.01669 0.6556 0.769
(R)-76 2.892  104 0.02028 0.7014 2.56
7Z 2.611  10 0.001931 73.97 0.775
L. Zhou et al. / Bioorg. Med. Chem. 20 (2012) 750–758 755We have demonstrated that (R)-76 and (R)-84 directly bind to
STAT6 and inhibit STAT6 phosphorylation. To our knowledge this
mode of STAT6 inhibition has not been previously reported. A tri-
cyclic heptaketide (TMC-264) was found in an IL-4 reporter screen
of microbial extracts, and the compound was reported both to
affect STAT6 tyrosine phosphorylation and to be less potent against
STAT1 phosphorylation.22 A series of STAT6 inhibitors based on
4-[(3-methylphenyl)amino]pyrimidine derivatives were screened
using IL-4R reporter assay, and their STAT6 binding status has
not been described.20,21 Compound 7Z was also originally discov-
ered by screening with a STAT6 reporter assay,27 and we have
shown here by SPR analysis that this inhibitor does not have mech-
anistically relevant afﬁnity for STAT6, with an observed KD at least
100-fold higher than that of (R)-76 and (R)-84.
4. Experimental
4.1. Synthesis
NMR spectra were recorded on a Varian AS400 MHz Nuclear
Magnetic Resonance Spectrometer with a multinuclear probe.Mass spectrometry analysis was performed on a Bruker Esquire
3000 plus LC/MS system using electrospray ionization method.
4.1.1. 4-(Benzo[b]thiophen-2-yl)pyridine-2,6-dicarboxylic acid
dimethyl ester (1)
A mixture of 4-bromopyridine-2,6-dicarboxylic acid methyl es-
ter (548 mg, 2.00 mmol), benzothiophene-2-boronic acid (401 mg,
Y641
pY641CC DBD L SH2
ND
V160
Parallel dimerAntiparallel dimer
JAK PJAKP
(R)-84
(R
)-8
4
(R
)-84
Figure 6. Schematic of STAT6 binding and inhibition by (R)-84. STAT6 domain structural features include,35 N-terminus domain (ND), coiled:coil domain (CC), DNA-binding
domain (DBD), linker domain (L), and SH2 domain (SH2). The tyrosine residue undergoes phosphorylation, Y641, is shown as a red dot after phosphorylation. V160 in the CC
domain corresponds to a residue that has been shown important in the formation of antiparallel structure of STAT1.35
756 L. Zhou et al. / Bioorg. Med. Chem. 20 (2012) 750–7582.25 mmol), sodium bicarbonate (332 mg, 3.95 mmol), and tetra-
kis(triphenylphosphine)palladium (119 mg, 0.10 mmol) was
placed in a 100 mL-ﬂask and dried under vacuum for 2.5 h. In a
separate ﬂask, a mixture of toluene (20 mL), methanol (5 mL) and
water (5 mL) was degassed by bubbling argon gas for 2.5 h, and
added to the ﬂask containing reagents. The resulting mixture was
stirred under argon atmosphere at 70 C for 2.5 h. The mixture
was cooled to room temperature and evaporated to dryness. The
residue was partitioned between dichloromethane and water,
and the organic phase was collected, washed with brine and dried
over sodium sulfate. After rotary evaporation, the residue was crys-
tallized from ethyl acetate–hexanes to afford 1 (488 mg) as a white
powder. Chromatography of the mother liquor on silica gel (10–
60% ethyl acetate in hexanes) afforded an additional 19 mg of the
product, providing 507 mg of 1 in total (77% yield). 1H NMR
(400 MHz, CDCl3) d 8.58 (s, 2H), 7.97 (s, 1H), 7.90 (m, 2H), 7.44
(m, 2H), 4.07 (s, 6H). 13C NMR (101 MHz, CDCl3) d 165.20,
149.12, 144.62, 140.48, 140.08, 138.87, 126.39, 125.42, 124.88,
124.50, 124.09, 122.76, 53.56.
4.1.2. 4-(Benzo[b]thiophen-2-yl)-6-(methoxycarbonyl) picolinic
acid (2)
To a mixture of dimethyl ester 1 (172 mg, 0.53 mmol) in meth-
anol (50 mL) and tetrahydrofuran (20 mL) was added 1 N aqueous
sodium hydroxide (0.55 mL, 0.55 mmol) and the resulting mixture
was stirred at room temperature for 28 h. The reaction was
quenched with 1 N aqueous hydrochloric acid (0.6 mL) and evapo-
rated to dryness. The residue was suspended with dichlorometh-
ane–methanol (v/v, 1:1) and ﬁltered through a pad of
diatomaceous earth. The ﬁltrate was evaporated and partitioned
between dichloromethane and water. The organic phase was col-
lected and dried over sodium sulfate. Evaporation of the solvents
afforded compound 2 (128 mg, 78% yield) as an orange solid, which
was used in next step without further puriﬁcation. 1H NMR
(400 MHz, DMSO-d6) d 13.74 (br s, 1H), 8.48 (m, 3H), 8.07 (m,
1H), 7.94 (m, 1H), 7.46 (m, 2H), 3.95 (s, 3H).4.1.3. (R)-4-(Benzo[b]thiophen-2-yl)-6-(3-methyl-butan-2-
ylcarbamoyl)picolinic acid methyl ester (3)
To a mixture of compound 2 (127 mg, 0.41 mmol) and 1-
hydroxybenzotriazole (HOBt, 99 mg, 0.73 mmol) in N,N-dimethyl-
formamide (DMF, 3 mL) was added 1-ethyl-3-dimethyl-aminopro-
pylcarbodiimide hydrochloride (EDCI, 123 mg, 0.64 mmol). The
mixture was stirred at room temperature for 15 min. A solution
of (R)-3-methyl-2-butylamine (41 mg, 0.47 mmol) in DMF (2 mL)
was added and the resulting mixture was stirred at room temper-
ature for 16 h. The mixture was diluted with dichloromethane,
washed with water, brine, and dried over sodium sulfate. Evapora-
tion of the solvents afforded a residue, which was chromato-
graphed on a silica gel (ethyl acetate–hexanes) to provide ester
amide 3 (109 mg, 70% yield). 1H NMR (400 MHz, CDCl3) d 8.67 (d,
J = 1.60 Hz, 1H), 8.47 (d, J = 1.60 Hz, 1H), 8.05 (br d, J = 9.20 Hz,
1H), 7.96 (s, 1H), 7.88 (m, 2H), 7.42 (m, 2H), 4.11 (m, 1H), 4.06
(s, 3H), 1.88 (m, 1H), 1.26 (d, J = 6.80 Hz, 3H), 1.01 (d, J = 6.80 Hz,
3H), 1.00 (d, J = 6.40 Hz, 3H).4.1.4. (R)-4-(Benzo[b]thiophen-2-yl)-6-(3-methylbutan-2-yl-
carbamoyl)picolinic acid (4)
To a solution of ester amide 3 (98 mg, 0.26 mmol) in tetrahy-
drofuran (4 mL) was added 1 N aqueous sodium hydroxide
(0.5 mL, 0.5 mmol) and the mixture was stirred at room tempera-
ture. After 13 h, the reaction was quenched by 1 N aqueous hydro-
chloric acid (0.5 mL) and evaporated to dryness. The residue was
partitioned between dichloromethane and half saturated brine.
The organic phase was collected and dried over sodium sulfate.
Evaporation of the solvents gave acid 4 (84 mg, 89% yield), which
was used in the next step without further puriﬁcation. 1H NMR
(400 MHz, DMSO-d6) d 13.30 (br s, 1H), 8.87 (d, J = 8.80 Hz, 1H),
8.49 (m, 3H), 8.07 (m, 1H), 7.93 (m, 1H), 7.45 (m, 2H), 3.90 (m,
1H), 1.81 (m, 1H), 1.18 (d, J = 6.80 Hz, 3H), 0.92 (d, J = 7.20 Hz,
3H), 0.90 (d, J = 7.20 Hz, 3H). ESI-MS: m/z [M+Na]+ 391.1, [M+H]+
369.2, [MH] 367.0.
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N6-(2-(pyridin-2-yl)ethyl)pyridine-2,6-dicarboxamide ((R)-76)
A mixture of compound 4 (79 mg, 0.21 mmol), 1-hydroxyben-
zotriazole (HOBt, 46 mg, 0.34 mmol) and 1-ethyl-3-dimethylami-
nopropylcarbodiimide hydrochloride (EDCI, 67 mg, 0.35 mmol) in
DMF (4 mL) was stirred at room temperature for 2 h. In a separate
ﬂask, 2-(2-aminoethyl)pyridine (24 mg, 0.20 mmol) was dissolved
in DMF (1 mL), to which 2 mL of the compound 4 solution prepared
above was added. After stirring at room temperature for 16 h, the
mixture was evaporated to dryness. The residue was dissolved in
dichloromethane, washed with water, brine, and dried over so-
dium sulfate. Evaporation of the solvent afforded a residue, which
was chromatographed on silica gel (ethyl acetate–hexanes) to pro-
vide diamide (R)-76 (36 mg, 71% yield) as colorless sticky oil. 1H
NMR (400 MHz, CDCl3) d 8.68 (t, J = 5.60 Hz, 1H), 8.61 (m, 2H),
8.56 (dd, J = 0.80, 4.00 Hz, 1H), 7.93 (s, 1H), 7.85 (m, 2H), 7.75 (d,
J = 9.20 Hz, 1H), 7.64 (dt, J = 1.60, 7.60 Hz, 1H), 7.38 (m, 2H), 7.23
(d, J = 8.00 Hz, 1H), 7.17 (dd, J = 5.00, 7.40 Hz, 1H), 4.11 (m, 1H),
3.97 (m, 2H), 3.18 (t, J = 6.20 Hz, 3H), 1.85 (m, 1H), 1.26 (d,
J = 6.40 Hz, 3H), 0.99 (d, J = 6.40 Hz, 3H), 0.98 (d, J = 6.80 Hz, 3H).
4.1.6. 4-(1-Methyl-1H-indol-2-yl)pyridine-2,6-dicarboxylic acid
dimethyl ester (5)
A mixture of 4-bromopyridine-2,6-dicarboxylic acid dimethyl
ester (548 mg, 2.00 mmol), 1-methylindole-2-boronic acid
(402 mg, 2.30 mmol), sodium bicarbonate (342 mg, 4.07 mmol),
and tetrakis(triphenylphosphine)palladium (68 mg, 0.08 mmol)
was placed in a 100 mL-ﬂask and dried under vacuum for 2.5 h.
In a separate ﬂask, a mixture of toluene (30 mL), methanol
(7.5 mL) and water (7.5 mL) was degassed by bubbling argon gas
for 2.5 h. The degassed solvent mixture was added to the dried re-
agents and the combined ingredients were stirred under argon
atmosphere at 70 C. After stirring for 19 h, the mixture was cooled
to room temperature, diluted with dichloromethane, washed with
brine and dried over sodium sulfate. After rotary evaporation, the
residue was puriﬁed using silica gel chromatography (40% ethyl
acetate in hexanes) to provide 5 (420 mg, 59% yield) as a light yel-
low solid. 1H NMR (400 MHz, CDCl3) d 8.47 (s, 2H), 7.69 (td, J = 1.00,
7.60 Hz, 1H), 7.42 (dd, J = 0.80, 8.40 Hz, 1H), 7.35 (dt, J = 1.20,
8.40 Hz, 1H), 7.20 (ddd, J = 1.20, 7.20, 8.00 Hz, 1H), 6.91 (d,
J = 0.80 Hz, 1H), 4.07 (s, 6H), 3.88 (s, 3H). 13C NMR (101 MHz,
CDCl3) d 165.26, 148.76, 143.28, 139.89, 136.60, 127.66, 127.00,
123.88, 121.62, 120.86, 110.23, 105.73, 53.54, 31.97.
4.1.7. 4-(1-Methyl-1H-indol-2-yl)pyridine-2,6-dicarboxylic acid
(6)
To a suspension of dimethyl ester 5 (418 mg, 1.28 mmol) in
methanol (15 mL) and tetrahydrofuran (5 mL) was added 1 N
aqueous sodium hydroxide (4 mL) and the mixture was stirred at
room temperature for 68 h. The reaction was quenched with 1 N
aqueous hydrochloric acid (4 mL) with ice-cooling and the mixture
was evaporated to dryness. The residue was suspended with meth-
anol–tetrahydrofuran (v/v = 3:1, 40 mL) and ﬁltered through a pad
of diatomaceous earth. The ﬁltrate was evaporated dryness, sus-
pended with methanol, and ﬁltered through a pad of diatomaceous
earth. Evaporation of the solvents afforded diacid 6 (387 mg, quan-
titative) as an orange solid, which was used for the next step with-
out further puriﬁcation. 1H NMR (400 MHz, DMSO-d6) d 8.36 (s,
2H), 7.65 (d, J = 7.60 Hz, 1H), 7.57 (dd, J = 2.00, 8.40 Hz, 1H), 7.28
(ddd, J = 1.20, 7.20, 8.40 Hz, 1H), 7.13 (ddd, J = 0.80, 7.20, 8.00 Hz,
1H), 7.00 (d, J = 0.80 Hz, 1H), 3.86 (s, 3H).
4.1.8. (R)-4-(1-Methyl-1H-indol-2-yl)-N2-(3-methylbutan-2-yl)-
N6-(2-(pyridin-2-yl)ethyl)pyridine-2,6-dicarboxamide ((R)-84)
A mixture of compound 6 (85 mg, 0.25 mmol), 1-hydroxyben-
zotriazole (83 mg, 0.61 mmol) and 1-ethyl-3-dimethylaminopro-pylcarbodiimide hydrochloride (EDCI, 105 mg, 0.55 mmol) in
DMF (4 mL) was stirred at room temperature for 2.5 h. A mixture
of 2-(2-aminoethyl)pyridine (30 mg, 0.25 mmol) and (R)-3-
methyl-2-butylamine (33 mg, 0.38 mmol) in DMF (1 mL) was
added with ice-cooling and the whole was stirred with ice-cooling
for 1 h then at room temperature. After stirring for 4 days, the mix-
ture evaporated to dryness and the residue was chromatographed
on silica gel to afford (R)-84 (46 mg, 39% yield). 1H NMR (400 MHz,
CDCl3) d 8.67 (br t, J = 5.60 Hz, 1H), 8.58 (ddd, J = 0.80, 1.60,
4.80 Hz, 1H), 8.51 (d, J = 1.60 Hz, 1H), 8.50 (d, J = 1.60 Hz, 1H),
7.73 (br d, J = 9.20 Hz, 1H), 7.68 (m, 1H), 7.65 (dt, J = 1.60,
7.60 Hz, 1H), 7.40 (dd, J = 0.80, 8.40 Hz, 1H), 7.32 (ddd, J = 1.20,
7.20, 8.40 Hz, 1H), 7.24 (d, J = 8.00 Hz, 1H), 7.18 (m, 2H), 6.89
(d, J = 0.80 Hz, 1H), 4.11 (m, 1H), 3.98 (m, 2H), 3.86 (s, 3H), 3.18
(t, J = 6.20 Hz, 2H), 1.87 (m, 1H), 1.27 (d, J = 6.80 Hz, 3H), 1.00
(d, J = 6.80 Hz, 3H), 0.99 (d, J = 6.40 Hz, 3H). ESI-MS: m/z [M+Na]+
492.2, [M+H]+ 470.3.
4.2. Cloning and expression of recombinant human STAT6
Full length human STAT6 gene was cloned into a pBac-based
baculovirus transfer vector. Sapphire DNA was used to create re-
combinant virus for P0. The P0 virus was used to produce P1 and
further P2 virus. The P2 virus was used to infect 1 L of Sf21 cells
at 1  106 cells/ml. Cells were collected three days after infection.
Cells were lysed in lysis buffer (1 PBS, pH7.4, 0.4% CHAPS,
0.05% Triton X-100, protease inhibitor tablet EDTA-free from
Roche, 10 mM BME). The recombinant STAT6 protein was puriﬁed
using Ni-NTA beads (Qiagen) to yield 24 mg/L of Sf21 cells. The
protein was dialyzed against PBS with 1 mM DTT, 1 mM EDTA,
and 10% glycerol, and used for both inhibitor screening and binding
characterizations.
For transient expression in mammalian cells, human STAT6 and
mouse STAT6 genes were cloned into the pEAK12 vector. The
resulting plasmids were used for studies involving 293-EBNA cells
and BEAS-2B cells as discussed below.
4.3. Cell based assays
4.3.1. STAT6 reporter assay and eotaxin-3 secretion ELISA assay
The STAT6 reporter construct was created by inserting six cop-
ies of IL-4 response element CTTCCCAAGAA into a construct that
expresses the Photinus luciferase gene.26 293-EBNA cells were
grown in 96-well plate to 90% conﬂuency. The cells were co-trans-
fected with the STAT6 reporter and human STAT6 using Lipofect-
amine2000 from Invitrogen. The transfected cells were changed
into serum free media after one day of transfection. The cells were
incubated with each compound for 1 h and then treated with
10 ng/ml IL-4 or control. After 6 h of induction, the cells were ana-
lyzed by luciferase activity using the Promega duo luciferase kit.
The experiments were performed in duplicates.
For eotaxin detection, BEAS-2B cells and A549 cells were grown
to 90% conﬂuency in DMEM and serum starved for 24 h. Each com-
pound was added to the cells for 1 h, followed by addition of IL-4 to
50 ng/mL concentration. The cells were further incubated for 24 h.
The media were collected and the amount of eotaxin-3 measured
by ELISA using the Duoset CCL26/eotaxin-3 kit (R&D Systems).
The experiments were performed in duplicates.
4.3.2. Immunoassay and immunoprecipitation
N-Terminal HA and myc tagged STAT plasmids were co-trans-
fected into 293-EBNA cells. The cells were serum starved after
growing in regular media for one day and treated with inhibitors
and IL-4 on the third day. The cells were washed once with PBS
and lysed in the lysis buffer (PBS, 0.05% Tween-20, protease
inhibitor cocktail EDTA-free). Each resulting lysate sample was
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for three times, boiled in sample buffer, and blotted with anti-HA,
anti-Myc, anti-STAT6 and anti-phospho-STAT6 antibodies.
4.4. Biochemical assays
4.4.1. STAT6 interaction with IL-4R derived peptides
IL-4 receptor derived peptide GASSGEEGYKPFQDLI was synthe-
sized by Invitrogen. The p-IL-4R peptide is phosphorylated at the
tyrosine residue, which is not phosphorylated in the control IL-
4R peptide. The peptides were biotinylated at the N-terminus. Re-
acti-bind™ streptavidin coated 96-well plate was coated with
20 lg/mL of each peptide in PBS. A mixture of each small molecule
inhibitor (20 lM) with various concentrations of recombinant
STAT6 was added to the plate and incubated at rt for 1 h. The
bound STAT6 was detected by anti-STAT6 mouse antibody and
anti-mouse HRP conjugate. The experiments were done in dupli-
cates or triplicates.
4.4.2. In vitro JAK2 kinase activity assay
HTScan JAK2 kinase assay kit (Cell Signaling Technology) was
used following the manufacturer’s instructions. Additional re-
agents used in this assay, including Stop solution, TMB solution,
and HRP-conjugated anti-mouse IgG antibody, were obtained from
Cell Signaling Technology. After incubation at room temperature
for 30 min, the reaction mixtures were transferred to a 96-well
streptavidin-coated plate (PerkinElmer). JAK2 activity was mea-
sured by colorimetric ELISA. The experiments were done in
triplicates.
4.4.3. STAT6-inhibitor binding assay using SPR
The experiments were performed on a BIAcore T100, using
Sensor Chip CM5 (Series S), amine coupling kit, and PBS buffer
from BIAcore.
Immobilization of STAT6 was performed at 25 C on sensor chip
CM5 (series S) in PBS running buffer (20 mM sodium phosphate,
150 mM sodium chloride, pH 7.4), at a ﬂow rate of 10 lL/min. Flow
cells were activated for 7 min by injecting a mixture of 50 mM NHS
and 200 mM EDC (70 lL). To prepare a high-capacity surface, 70 lL
of STAT6 solution (25 lg/mL) in sodium acetate buffer (pH 5.0) was
injected for 7 min, followed by injection of 70 lL ethanolamine to
block any remaining surface-activated groups. Typical immobiliza-
tion levels ranged from 12,000 to 14,000 RU. Non-derivatized ﬂow
cells served as reference surfaces.
All the assays were performed at 25 C on the sensor chip de-
scribed above. All compounds were stored as 10 mM stock solu-
tions in dimethyl sulfoxide (DMSO). After dilution to 2 mM with
DMSO, each sample was mixed with 1.05-fold concentrated assay
buffer and DMSO to yield a 100 lM compound solution in pH 7.4
buffer with a ﬁnal composition of 20 mM sodium phosphate,
150 mM sodium chloride, and 5% DMSO, which was also used as
the instrument running buffer and sample dilution buffer. All as-
says were run at a ﬂow rate of 30 lL/min and a data collection rate
of 10 Hz. Each run was started with ﬁve start-up cycles in which
running buffer was injected instead of sample, followed by sample
injection cycles. A duplicate sample and a zero concentration sam-
ple were used as a positive and negative control. A typical analysis
cycle consisted of a 60 s sample injection, 600 s of buffer ﬂow (dis-
sociation phase), followed by a wash with 25% DMSO and buffer,
and ﬁnally a 30 s buffer injection to check for sample carryover. Be-
tween sample series, several solvent correction cycles were run to
adjust for referencing errors due to refractive index mismatches
between running buffer and samples.
Calculated equilibrium dissociation constants (KD), association
rate (ka), and dissociation rate (kd) were obtained by global ﬁtting
of SPR sensorgrams to a 1:1 Langmuir binding model. The v2 valuerepresents the sum of squared differences between the experimen-
tal data and reference data at each point of the ﬁt.
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